WHO | People who inject drugs. WHO. 2016. http://www.who.int/hiv/topics/idu/about/en/. Accessed 14 Feb 2018.
MacArthur GJ, van Velzen E, Palmateer N, Kimber J, Pharris A, Hope V, et al. Interventions to prevent HIV and hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness. Int J Drug Policy. 2014;25:34–52. https://doi.org/10.1016/j.drugpo.2013.07.001.
Burnett JC, Broz D, Spiller MW, Wejnert C, Paz-Bailey G. HIV infection and HIV-associated behaviors among persons who inject drugs - 20 cities, United States, 2015. MMWR Morb Mortal Wkly Rep. 2018;67:23–8. https://doi.org/10.15585/mmwr.mm6701a5.
Conrad C, Bradley HM, Broz D, Buddha S, Chapman EL, Galang RR, et al. Community outbreak of HIV infection linked to injection drug use of Oxymorphone--Indiana, 2015. MMWR Morb Mortal Wkly Rep. 2015;64:443–4 http://www.ncbi.nlm.nih.gov/pubmed/25928470.
Vickerman P, Hickman M, May M, Kretzschmar M, Wiessing L. Can hepatitis C virus prevalence be used as a measure of injection-related human immunodeficiency virus risk in populations of injecting drug users? An ecological analysis. Addiction. 2010;105:311–8. https://doi.org/10.1111/j.1360-0443.2009.02759.x.
World Health Organization. WHO expands recommendation on oral pre-exposure prophylaxis of HIV infection (PrEP): policy brief. Available at: http://apps.who.int/iris/bitstream/10665/197906/1/WHO_HIV_2015.48_eng.pdf. 2015.
Tan DHS, Hull MW, Yoong D, Tremblay C, O’Byrne P, Thomas R, et al. Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis. CMAJ. 2017;189:E1448–58. https://doi.org/10.1503/cmaj.170494.
Center for Disease Control and Prevention. Preexposure Prophylaxis for the Prevention of Hiv Infection in The United States-2017 Update A Clinical Practice Guideline. 2017. https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf-. Accessed 18 Oct 2018.
Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381:2083–90. https://doi.org/10.1016/S0140-6736(13)61127-7.
Spinner CD, Boesecke C, Zink A, Jessen H, Stellbrink HJ, Rockstroh JK, et al. HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans. Infection. 2016;44:151–8. https://doi.org/10.1007/s15010-015-0850-2.
Martin M, Vanichseni S, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. The impact of adherence to preexposure prophylaxis on the risk of HIV infection among people who inject drugs. AIDS. 2015;29:819–24. https://doi.org/10.1097/QAD.0000000000000613.
Martin M, Vanichseni S, Suntharasamai P, Sangkum U, Mock PA, Chaipung B, et al. Factors associated with the uptake of and adherence to HIV pre-exposure prophylaxis in people who have injected drugs: an observational, open-label extension of the Bangkok Tenofovir study. Lancet HIV. 2017;4:e59–66. https://doi.org/10.1016/S2352-3018(16)30207-7.
Escudero DJ, Lurie MN, Kerr T, Howe CJ, Marshall BD. HIV pre-exposure prophylaxis for people who inject drugs: a review of current results and an agenda for future research. J Int AIDS Soc. 2014;17:18899. https://doi.org/10.7448/IAS.17.1.18899.
Biello K, Bazzi A, Mimiaga M, Biancarelli D, Edeza A, Salhaney P, et al. Perspectives on HIV pre-exposure prophylaxis (PrEP) utilization and related intervention needs among people who inject drugs. Harm Reduct J. 2018;15(1):55. https://doi.org/10.1186/s12954-018-0263-5.
Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73:691–705. https://doi.org/10.1111/j.1365-2125.2012.04167.x.
Malta M, Magnanini MM, Strathdee SA, Bastos FI. Adherence to antiretroviral therapy among HIV-infected drug users: a meta-analysis. AIDS Behav. 2010;14:731–47. https://doi.org/10.1007/s10461-008-9489-7.
Wood E, Kerr T, Montaner JSG. HIV treatment, injection drug use, and illicit drug policies. Lancet. 2007;370:8–10.
Gonzalez JS, Batchelder AW, Psaros C, Safren SA. Depression and HIV/AIDS treatment nonadherence: a review and meta-analysis. J Acquir Immune Defic Syndr. 2011;58:181–7. https://doi.org/10.1097/QAI.0b013e31822d490a.
Altice FL, Kamarulzaman A, Soriano VV, Schechter M, Friedland GH. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet. 2010;376:367–87.
Mayer KH, Safren SA, Elsesser SA, Psaros C, Tinsley JP, Marzinke M, et al. Optimizing Pre-Exposure Antiretroviral Prophylaxis Adherence in Men Who Have Sex with Men: Results of a Pilot Randomized Controlled Trial of "Life-Steps for PrEP". AIDS Behav. 2017;21:1350–60. https://doi.org/10.1007/s10461-016-1606-4.
Gelberg L, Andersen RM, Leake BD. The behavioral model for vulnerable populations: application to medical care use and outcomes for homeless people. Health Serv Res. 2000;34:1273–302 http://www.ncbi.nlm.nih.gov/pubmed/10654830.
Levac D, Colquhoun H, O’Brien KK. Scoping studies: advancing the methodology. Implement Sci. 2010;5:69. https://doi.org/10.1186/1748-5908-5-69.
Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535. https://doi.org/10.1136/BMJ.B2535.
Popay J, Roberts H, Sowden A, Petticrew M, Arai L, Rodgers M, et al. Guidance on the conduct of narrative synthesis in systematic reviews. A Prod from ESRC Methods Program. 2006;2006:211–9.
Hadland SE, Milloy MJ, Kerr T, Zhang R, Guillemi S, Hogg RS, et al. Young age predicts poor antiretroviral adherence and viral load suppression among injection drug users. AIDS Patient Care STDs. 2012;26:274–80. https://doi.org/10.1089/apc.2011.0196.
Kang SY, Deren S, Colon HM. Differential gender effects of depression on use of HIV medications among HIV-positive Puerto Rican drug users. AIDS Care. 2011;23:1467–71. https://doi.org/10.1080/09540121.2011.565022.
Tapp C, Milloy MJ, Kerr T, Zhang R, Guillemi S, Hogg RS, et al. Female gender predicts lower access and adherence to antiretroviral therapy in a setting of free healthcare. BMC Infect Dis. 2011;11:86. https://doi.org/10.1186/1471-2334-11-86.
Palepu A, Milloy MJ, Kerr T, Zhang R, Wood E. Homelessness and adherence to antiretroviral therapy among a cohort of HIV-infected injection drug users. J Urban Heal. 2011;88:545–55. https://doi.org/10.1007/s11524-011-9562-9.
Joseph B, Kerr T, Puskas CM, Montaner J, Wood E, Milloy MJ. Factors linked to transitions in adherence to antiretroviral therapy among HIV-infected illicit drug users in a Canadian setting. AIDS Care. 2015;27:1128–36. https://doi.org/10.1080/09540121.2015.1032205.
Westergaard RP, Hess T, Astemborski J, Mehta SH, Kirk GD. Longitudinal changes in engagement in care and viral suppression for HIV-infected injection drug users. AIDS. 2013;27:2559–66. https://doi.org/10.1097/QAD.0b013e328363bff2.
Kavasery R, Astemborski J, Lucas GM, Celentano DD, Kirk GD, Mehta SHGN. Nonstructured treatment interruptions among injection drug users in Baltimore, MD. JAIDS. 2009;50:6.
Palepu A, Tyndall MW, Joy R, Kerr T, Wood E, Press N, et al. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy. Drug Alcohol Depend. 2006;84:188–94. https://doi.org/10.1016/j.drugalcdep.2006.02.003.
Knowlton A, Eldred L, Wilkinson J, Gourevitch M, Shade S, Dowling K, Purcell D, INSPIRE TAJ. Individual, interpersonal, and structural correlates of effective HAART use among urban active injection drug users. JAIDS. 2006;41:6.
Knowlton AR, Arnsten JH, Eldred LJ, Wilkinson JD, Shade SB, Bohnert AS, et al. Antiretroviral use among active injection-drug users: the role of patient-provider engagement and structural factors. AIDS Patient Care STDs. 2010;24:421–8. https://doi.org/10.1089/apc.2009.0240.
Bruce RD. Is it time for treatment as prevention among people who inject drugs? J Acquir Immune Defic Syndr. 2013;63:545–7 https://journals.lww.com/jaids/fulltext/2013/08150/Is_It_Time_for_Treatment_as_Prevention_Among.1.aspx?casa_token=1mBWHJPN4JkAAAAA:G5SqgaqeOrLNXS0KGC2-RMKr8hxnE3yLK-b1w--mx4RigdPjbyGe8QH1T3ghedm9dqkx-ozzsFhQBP_uba-NQSFv.
Gallagher KM, Updegraff JA. Health message framing effects on attitudes, intentions, and behavior: a meta-analytic review. Ann Behav Med. 2012;43:101–16. https://doi.org/10.1007/s12160-011-9308-7.
Hosek SG, Rudy B, Landovitz R, Kapogiannis B, Siberry G, Rutledge B, et al. An HIV Preexposure prophylaxis demonstration project and safety study for young MSM. JAIDS J Acquir Immune Defic Syndr. 2017;74:21–9. https://doi.org/10.1097/QAI.0000000000001179.
Page K, Tsui J, Maher L, Choopanya K, Vanichseni S, Mock PA, et al. Biomedical HIV prevention including pre-exposure prophylaxis and opiate agonist therapy for women who inject drugs: state of research and future directions. J Acquir Immune Defic Syndr. 2015;69(Suppl 2):S169–75. https://doi.org/10.1097/QAI.0000000000000641.
Liu AY, Hessol NA, Vittinghoff E, Amico KR, Kroboth E, Fuchs J, et al. Medication adherence among men who have sex with men at risk for HIV infection in the United States: implications for pre-exposure prophylaxis implementation. AIDS Patient Care STDs. 2014;28:622–7. https://doi.org/10.1089/apc.2014.0195.
Altice FL, Springer S, Buitrago M, Hunt DP, Friedland GH. Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users. J Urban Heal. 2003;80:416–27. https://doi.org/10.1093/jurban/jtg053.
Kushel MB, Colfax G, Ragland K, Heineman A, Palacio H, Bangsberg DR. Case management is associated with improved antiretroviral adherence and CD4+ cell counts in homeless and marginally housed individuals with HIV infection. Clin Infect Dis. 2006;43:234–42. https://doi.org/10.1086/505212.
Azar P, Wood E, Nguyen P, Luma M, Montaner J, Kerr T, et al. Drug use patterns associated with risk of non-adherence to antiretroviral therapy among HIV-positive illicit drug users in a Canadian setting: a longitudinal analysis. BMC Infect Dis. 2015;15:193. https://doi.org/10.1186/s12879-015-0913-0.
Andersen R, Bozzette S, Shapiro M, St Clair P, Morton S, Crystal S, et al. Access of vulnerable groups to antiretroviral therapy among persons in care for HIV disease in the United States. HCSUS consortium. HIV cost and services utilization study. Health Serv Res. 2000;35:389–416 https://www.ncbi.nlm.nih.gov/pubmed/10857469.
Ing EC, Bae JW, Maru DS, Altice FL. Medication persistence of HIV-infected drug users on directly administered antiretroviral therapy. AIDS Behav. 2013;17:113–21. https://doi.org/10.1007/s10461-011-0082-0.
Cunningham CO, Sohler NL, Cooperman NA, Berg KM, Litwin AH, Arnsten JH. Strategies to improve access to and utilization of health care services and adherence to antiretroviral therapy among HIV-infected drug users. Subst Use Misuse. 2011;46:218–32. https://doi.org/10.3109/10826084.2011.522840.
Arnsten JH, Li X, Mizuno Y, Knowlton AR, Gourevitch MN, Handley K, et al. Factors associated with antiretroviral therapy adherence and medication errors among HIV-infected injection drug users. JAIDS J Acquir Immune Defic Syndr. 2007;46(Supplement 2):S64–71. https://doi.org/10.1097/QAI.0b013e31815767d6.
Wood E, Kerr T, Tyndall MW, Montaner JS. A review of barriers and facilitators of HIV treatment among injection drug users. AIDS. 2008;22:1247–56. https://doi.org/10.1097/QAD.0b013e3282fbd1ed.
Magnani R, Sabin K, Saidel T, Heckathorn D. Review of sampling hard-to-reach and hidden populations for HIV surveillance. AIDS. 2005;19(Suppl 2):S67–72 http://www.ncbi.nlm.nih.gov/pubmed/15930843.
Altice FL, Maru DS, Bruce RD, Springer SA, Friedland GH. Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trial. Clin Infect Dis. 2007;45:770–8. https://doi.org/10.1086/521166.
Purcell DW, Metsch LR, Latkin CA, Gómez CA, Mizuno Y, Arnsten JH, Wilkinson JD, Knight KR, Knowlton AR, Santibanez S, Tobin KE, Rose CD, Valverde EE, Gourevitch MN, Eldred L, Borkowf CB, INSPIRE Study Team. LMH. Results from a randomized controlled Trialof a peer-mentoring intervention to reduce HIV transmission and increase access to care and adherence to HIV medications among HIV-seropositive injection drug users. JAIDS. 2007;46.
Waldrop-Valverde D, Jones DL, Weiss S, Kumar M, Metsch L. The effects of low literacy and cognitive impairment on medication adherence in HIV-positive injecting drug users. Acquir Immune Defic Syndr. 2007;46 Suppl 2:S35–47. https://doi.org/10.1097/QAI.0b013e31815767c4.
Bach P, Wood E, Dong H, Guillemi S, Kerr T, Montaner J, et al. Association of patterns of methadone use with antiretroviral therapy discontinuation: a prospective cohort study. BMC Infect Dis. 2015;15:537. https://doi.org/10.1186/s12879-015-1255-7.
Reddon H, Milloy MJ, Simo A, Montaner J, Wood E, Kerr T. Methadone maintenance therapy decreases the rate of antiretroviral therapy discontinuation among HIV-positive illicit drug users. AIDS Behav. 2014;18:740–6. https://doi.org/10.1007/s10461-013-0584-z.
Uhlmann S, Milloy MJ, Kerr T, Zhang R, Guillemi S, Marsh D, et al. Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug users. Addiction. 2010;105:907–13. https://doi.org/10.1111/j.1360-0443.2010.02905.x.
Haberer JE, Bangsberg DR, Baeten JM, Curran K, Koechlin F, Amico KR, et al. Defining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigm. AIDS. 2015;29:1277–85. https://doi.org/10.1097/QAD.0000000000000647.
Gonzalez A, Mimiaga MJ, Israel J, Andres Bedoya C, Safren SA. Substance use predictors of poor medication adherence: the role of substance use coping among HIV-infected patients in opioid dependence treatment. AIDS Behav. 2013;17:168–73. https://doi.org/10.1007/s10461-012-0319-6.